相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
HER2-targeted therapies in gastric cancer
Yinxing Zhu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
Hui K. Gan et al.
ONCOLOGIST (2021)
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Hamid Maadi et al.
CANCERS (2021)
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Mouade El Bali et al.
JOURNAL OF ONCOLOGY (2021)
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Andriy Marusyk et al.
CANCER CELL (2020)
Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation
Sofia del Carmen et al.
SCIENTIFIC REPORTS (2020)
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Alberto Ocana et al.
BREAST CANCER RESEARCH (2020)
Overall survival of colorectal cancer by stage at diagnosis Data from the Martinique Cancer Registry
Clarisse Joachim et al.
MEDICINE (2019)
Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication]
Kenjiro Kotake
JOURNAL OF THE ANUS RECTUM AND COLON (2019)
Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis
Ji-Lin Li et al.
BMC CLINICAL PATHOLOGY (2019)
HER2: An emerging target in colorectal cancer
Megan Greally et al.
CURRENT PROBLEMS IN CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Variability in HER2 expression between primary colorectal cancer and corresponding metastases
Lina Shan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
HER3 signaling and targeted therapy in cancer
Rosalin Mishra et al.
ONCOLOGY REVIEWS (2018)
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
Richard Adams et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer
Yoshifumi Shimada et al.
HUMAN PATHOLOGY (2017)
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience
Jun Gong et al.
ONCOTARGET (2017)
Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy
Maria Villalba et al.
CELL AND TISSUE RESEARCH (2017)
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer
Arndt Stahler et al.
ANTI-CANCER DRUGS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
HER3 expression is correlated to distally located and low-grade colon cancer
Frida Ledel et al.
ACTA ONCOLOGICA (2016)
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
Soo Kyung Nam et al.
PLOS ONE (2016)
Multisciplinary management of patients with liver metastasis from colorectal cancer
Kathleen De Greef et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver
Frida Ledel et al.
ACTA ONCOLOGICA (2015)
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
Wafik S. El-Deiry et al.
CANCER BIOLOGY & THERAPY (2015)
HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value
An Na Seo et al.
VIRCHOWS ARCHIV (2015)
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
Hanna Styczen et al.
ONCOTARGET (2015)
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases
J. A. C. M. Goos et al.
BRITISH JOURNAL OF CANCER (2014)
HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome
F. Ledel et al.
EUROPEAN JOURNAL OF CANCER (2014)
Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma
Enken Drecoll et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system
Sadaf Farzand et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases
Won-Suk Lee et al.
CANCER MEDICINE (2014)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread
Robert L. Ferris et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
Qingguo Li et al.
BMC CANCER (2011)
Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Li-Chen Yen et al.
ANNALS OF SURGERY (2010)
EGFR expression variance in paired colorectal cancer primary and metastatic tumors
Nirit Yarom et al.
CANCER BIOLOGY & THERAPY (2010)
Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases
Hidekazu Kuramochi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL CANCER RESEARCH (2010)
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Dara O. Kavanagh et al.
BMC CANCER (2009)
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
F. Molinari et al.
BRITISH JOURNAL OF CANCER (2009)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer
Frank E. Jones
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Natalia V. Sergina et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
M. Scartozzi et al.
BRITISH JOURNAL OF CANCER (2007)
HER 2/neu protein expression in colorectal cancer
B. Schuell et al.
BMC CANCER (2006)
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites:: biological and clinical implications
A Italiano et al.
ANNALS OF ONCOLOGY (2005)
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:: an immunohistochemical and fluorescent in situ hybridization study
A Ooi et al.
MODERN PATHOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
